Sobi licenses lacutamab from Innate Pharma

French rare diseases company Innate Pharma (Euronext Paris: IPH) and Swedish Orphan Biovitrum (STO: SOBI; Sobi) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase III study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Innate’s shares leapt more than 20% to 1.83 francs on the news.

Under the agreement, Innate will conduct the TELLOMAK-3 Phase III confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in Sézary syndrome and mycosis fungoides, the most common subtype.